These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 20150371)

  • 21. Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study.
    Jakacki RI; Hamilton M; Gilbertson RJ; Blaney SM; Tersak J; Krailo MD; Ingle AM; Voss SD; Dancey JE; Adamson PC
    J Clin Oncol; 2008 Oct; 26(30):4921-7. PubMed ID: 18794549
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.
    Norden AD; Raizer JJ; Abrey LE; Lamborn KR; Lassman AB; Chang SM; Yung WK; Gilbert MR; Fine HA; Mehta M; Deangelis LM; Cloughesy TF; Robins HI; Aldape K; Dancey J; Prados MD; Lieberman F; Wen PY
    J Neurooncol; 2010 Jan; 96(2):211-7. PubMed ID: 19562255
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.
    Prados MD; Chang SM; Butowski N; DeBoer R; Parvataneni R; Carliner H; Kabuubi P; Ayers-Ringler J; Rabbitt J; Page M; Fedoroff A; Sneed PK; Berger MS; McDermott MW; Parsa AT; Vandenberg S; James CD; Lamborn KR; Stokoe D; Haas-Kogan DA
    J Clin Oncol; 2009 Feb; 27(4):579-84. PubMed ID: 19075262
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas.
    Grossman SA; Carson KA; Phuphanich S; Batchelor T; Peereboom D; Nabors LB; Lesser G; Hausheer F; Supko JG;
    Neuro Oncol; 2008 Aug; 10(4):608-16. PubMed ID: 18577560
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing anticonvulsants: an NCIC CTG study.
    Mason WP; Macneil M; Kavan P; Easaw J; Macdonald D; Thiessen B; Urva S; Lwin Z; McIntosh L; Eisenhauer E
    Invest New Drugs; 2012 Dec; 30(6):2344-51. PubMed ID: 22160854
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.
    Wen PY; Yung WK; Lamborn KR; Dahia PL; Wang Y; Peng B; Abrey LE; Raizer J; Cloughesy TF; Fink K; Gilbert M; Chang S; Junck L; Schiff D; Lieberman F; Fine HA; Mehta M; Robins HI; DeAngelis LM; Groves MD; Puduvalli VK; Levin V; Conrad C; Maher EA; Aldape K; Hayes M; Letvak L; Egorin MJ; Capdeville R; Kaplan R; Murgo AJ; Stiles C; Prados MD
    Clin Cancer Res; 2006 Aug; 12(16):4899-907. PubMed ID: 16914578
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study.
    Chheda MG; Wen PY; Hochberg FH; Chi AS; Drappatz J; Eichler AF; Yang D; Beroukhim R; Norden AD; Gerstner ER; Betensky RA; Batchelor TT
    J Neurooncol; 2015 Feb; 121(3):627-34. PubMed ID: 25503302
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.
    Reardon DA; Quinn JA; Vredenburgh JJ; Gururangan S; Friedman AH; Desjardins A; Sathornsumetee S; Herndon JE; Dowell JM; McLendon RE; Provenzale JM; Sampson JH; Smith RP; Swaisland AJ; Ochs JS; Lyons P; Tourt-Uhlig S; Bigner DD; Friedman HS; Rich JN
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):860-8. PubMed ID: 16467100
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase I dose-escalation study of fractionated stereotactic radiosurgery in combination with gefitinib in patients with recurrent malignant gliomas.
    Schwer AL; Damek DM; Kavanagh BD; Gaspar LE; Lillehei K; Stuhr K; Chen C
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):993-1001. PubMed ID: 17967517
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma.
    Kuhn JG; Chang SM; Wen PY; Cloughesy TF; Greenberg H; Schiff D; Conrad C; Fink KL; Robins HI; Mehta M; DeAngelis L; Raizer J; Hess K; Lamborn KR; Dancey J; Prados MD;
    Clin Cancer Res; 2007 Dec; 13(24):7401-6. PubMed ID: 18094423
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen.
    Cloughesy TF; Filka E; Kuhn J; Nelson G; Kabbinavar F; Friedman H; Miller LL; Elfring GL
    Cancer; 2003 May; 97(9 Suppl):2381-6. PubMed ID: 12712460
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma.
    Nabors LB; Supko JG; Rosenfeld M; Chamberlain M; Phuphanich S; Batchelor T; Desideri S; Ye X; Wright J; Gujar S; Grossman SA;
    Neuro Oncol; 2011 Dec; 13(12):1324-30. PubMed ID: 21954442
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma.
    Reardon DA; Groves MD; Wen PY; Nabors L; Mikkelsen T; Rosenfeld S; Raizer J; Barriuso J; McLendon RE; Suttle AB; Ma B; Curtis CM; Dar MM; de Bono J
    Clin Cancer Res; 2013 Feb; 19(4):900-8. PubMed ID: 23363814
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma.
    Reardon DA; Desjardins A; Vredenburgh JJ; Sathornsumetee S; Rich JN; Quinn JA; Lagattuta TF; Egorin MJ; Gururangan S; McLendon R; Herndon JE; Friedman AH; Salvado AJ; Friedman HS
    Neuro Oncol; 2008 Jun; 10(3):330-40. PubMed ID: 18359865
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant glioma.
    Phuphanich S; Carson KA; Grossman SA; Lesser G; Olson J; Mikkelsen T; Desideri S; Fisher JD;
    Neuro Oncol; 2008 Aug; 10(4):617-23. PubMed ID: 18477765
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study.
    Loghin ME; Prados MD; Wen P; Junck L; Lieberman F; Fine H; Fink KL; Metha M; Kuhn J; Lamborn K; Chang SM; Cloughesy T; DeAngelis LM; Robins IH; Aldape KD; Yung WK
    Clin Cancer Res; 2007 Dec; 13(23):7133-8. PubMed ID: 18056194
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.
    van den Bent MJ; Brandes AA; Rampling R; Kouwenhoven MC; Kros JM; Carpentier AF; Clement PM; Frenay M; Campone M; Baurain JF; Armand JP; Taphoorn MJ; Tosoni A; Kletzl H; Klughammer B; Lacombe D; Gorlia T
    J Clin Oncol; 2009 Mar; 27(8):1268-74. PubMed ID: 19204207
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients.
    Van Cutsem E; Verslype C; Beale P; Clarke S; Bugat R; Rakhit A; Fettner SH; Brennscheidt U; Feyereislova A; Delord JP
    Ann Oncol; 2008 Feb; 19(2):332-9. PubMed ID: 17986625
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma.
    Reardon DA; Egorin MJ; Desjardins A; Vredenburgh JJ; Beumer JH; Lagattuta TF; Gururangan S; Herndon JE; Salvado AJ; Friedman HS
    Cancer; 2009 May; 115(10):2188-98. PubMed ID: 19248046
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma.
    de Groot JF; Gilbert MR; Aldape K; Hess KR; Hanna TA; Ictech S; Groves MD; Conrad C; Colman H; Puduvalli VK; Levin V; Yung WK
    J Neurooncol; 2008 Oct; 90(1):89-97. PubMed ID: 18581057
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.